ABSTRACT
A number of liposomal and lipid-based products have reached the market, with a full pipeline of similar products in clinical trials or preclinical development (1). In spite of this, there is not a good understanding of how the physical properties of the various drug formulations affect the pharmacokinetics (PK) and biopharmaceutics (BP) of their associated drugs relative to free (conventional) drugs.
